NeoPharm Co

NeoPharm Co Forward P/E

The Forward P/E Ratio of NeoPharm Co (092730.KQ) as of Nov 3, 2026 is 10.19. In the previous year, Forward P/E Ratio was 12.29 — a change of -17.10% (lower).

Forward P/E

10.19

YoY

-17.10%

Last updated:

Forward P/E Ratio of NeoPharm Co is 2025 10.19 . Forward P/E Ratio of NeoPharm Co was 2024 12.29 . It decreases by -17.10% lower compared to the previous year.

The NeoPharm Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
18.45 KRW
Jan 1, 2019
14.73 KRW
Jan 1, 2020
15.64 KRW
Jan 1, 2021
16.01 KRW
Jan 1, 2022
16.65 KRW
Jan 1, 2023
12.22 KRW
Jan 1, 2024
12.29 KRW
Jan 1, 2025
10.19 KRW
The NeoPharm Co Forward P/E history
YEARForward P/EYoY
10.19-17.10%
12.29+0.64%
12.22-26.65%
16.65+4.03%
16.01+2.36%
15.64+6.15%
14.73-20.14%
18.45-24.79%
24.53-33.02%
36.63-55.99%
83.23-24.63%
110.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoPharm Co Stock analysis

What does NeoPharm Co do? NeoPharm Co., Ltd. generates revenue through the development, manufacture, and sale of cosmetics, medical, and health products under its own brand names. The company sells ATOPALM products, which include daily care, intensive care, special care, and baby care items, as well as Derma:B products such as foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, BB creams, sun protectors, white watering serums, and anti-aging eye creams. ZEROID products, featuring creams and lotions for skin barrier recovery and hypoallergenic foaming cleansers for atopic and sensitive skin, also contribute to sales. Additionally, NeoPharm provides original equipment manufacturing (OEM) services for skin drugs, supplying these to other companies. The primary buyers of NeoPharm's products are consumers seeking skincare solutions for daily use, sensitive skin conditions, and medical-grade treatments. ATOPALM targets general skincare and baby care markets, while Derma:B appeals to users looking for comprehensive skincare routines including anti-aging and sun protection. ZEROID focuses on individuals with atopic or sensitive skin requiring gentle, hypoallergenic products. OEM services are purchased by other pharmaceutical companies needing skin drug manufacturing capabilities. NeoPharm's product portfolio is structured around four key brands: ATOPALM, Derma:B, ZEROID, and OEM services. ATOPALM and Derma:B cater to broad consumer segments in the cosmetics and skincare industry, with Derma:B offering a wide range of products for various skin concerns. ZEROID serves a specialized segment for sensitive skin care, and OEM services target business-to-business clients in the pharmaceutical sector. The company's revenue streams are thus diversified across consumer-facing brands and B2B manufacturing contracts. NeoPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeoPharm Co stock

Forward P/E Ratio of NeoPharm Co is 10.19 in 2025.

Forward P/E Ratio of NeoPharm Co changed from 12.29 to 10.19, representing a -17.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio NeoPharm Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's NeoPharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — NeoPharm Co

All Key Metrics — NeoPharm Co